

[View this email in your browser](#)

MORE TIME, MORE OPTIONS

CLINICAL TRIALS NEWSLETTER

As 2025 comes to a close, we're reflecting on what this community has made possible. Because of your support, determination, and trust in science, **Fight CRC** [shared more than 50 new and ongoing clinical trials this year](#), helping patients and caregivers access more options and more hope.

Your advocacy, curiosity, and generosity make this possible. Every donation, every share, and every conversation helps move research forward, creating more time for people living with colorectal cancer.

[DONATE TO OUR END-OF-YEAR RESEARCH GOAL!](#)

CLINICAL TRIAL ROUNDUP

This month's featured trials spotlight emerging options for MSS colorectal cancer, including next-generation immunotherapy combinations, KRAS G12C-targeted strategies, and ctDNA-guided treatment decisions.

From early-line targeted approaches to innovative CAR-T and third-line IO combos, these studies reflect a growing focus on overcoming resistance and personalizing care for people with CRC.

[READ THE FULL LIST OF DECEMBER CLINICAL TRIALS](#)

Disclaimer: Inclusion in this list does not imply endorsement or a guaranteed benefit. Always consult your healthcare provider to determine whether a clinical trial is appropriate for you.

BEHIND THE RESEARCH

>>> Register at: [FIGHTCRC.ORG/WEBINARS](https://fightcrc.org/webinars)

FIGHTCRC



INSIDE XDRIVE: WHAT FUNCTIONAL PRECISION MEDICINE COULD MEAN FOR CRC PATIENTS

ONLINE WEBINAR

DEC. 18 @ 6-7PM EST

Join us for an eye-opening webinar on **December 18** featuring experts from [First Ascent Biomedical](#) and a [Fight CRC Research Advocate](#), as we dive into *Inside xDRIVE*: an innovative, Fight CRC–funded clinical study, bringing functional precision medicine to the forefront.

DON'T MISS THIS! REGISTER TODAY

SPOTLIGHT

A Year of Gratitude



2025 has been a year of progress powered by people! Our advocates, researchers, partners, and supporters believe that More Time and More Options aren't just goals, but a shared responsibility.

To Our Research and Industry Partners:

[Pfizer](#), [Exact Sciences](#), [Boehringer Ingelheim](#), [Tempus](#), [First Ascent Bio](#), and the [Ron & Martha Doornink Foundation](#) — thank you for championing innovation and investing in science that gives patients new choices and renewed hope.

To Our Research and Industry Partners:

To our curators, the [Research Advocacy Training and Support \(RATS\) program](#), attendees, senior advisors (Dr. Andy Chan, Dr. Jose Perea, and Andrea Dwyer) of the first-ever [Global Think Tank on Early Onset CRC \(EOCRC\)](#), and EOCRC Workgroups and Advisory Committee — all who keep patients at the heart of discovery. Your efforts strengthen the bridge between science and advocacy and help shape the research priorities that matter most.

Thank You to Our Research Community



Our Board of Directors, Medical Advisory Board, and the Hereditary & Genetics Workgroup — thank you for your expertise, vision, and relentless drive to lead with science, compassion, and urgency. Because of your guidance, our advocacy reaches further, our research impact grows stronger, and our community never stops fighting for a cure.

Together, we're showing that progress isn't measured in data points — it's measured in the moments we help create: more time with loved ones, more treatment options, and more hope for what's ahead.

ACTION AND AWARENESS

***We want to hear from you:** Looking ahead to 2026, which innovation do you believe will have the greatest impact on colorectal cancer treatment?*

WE WANT TO KNOW!



[Take the Quiz!](#)



[Ask Now!](#)



[Search Now!](#)

DONATE TO SUPPORT OUR RESEARCH



© Copyright 2025 Fight Colorectal Cancer
FightCRC.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe](#)